Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Weight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper understands. A five-year trial of the weight loss drug tirzepatide in ...

In this trial, both drugs helped improve these health markers, but tirzepatide’s added benefits could make it the top choice for many people with obesity. Still, not every patient will need the ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

Tirzepatide's dual effects on GLP-1 and GIP may explain its superior performance. Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

The tirzepatide group had more injection-site reactions than the semaglutide group, which is consistent with other SURMOUNT trials. 14,20 In the current trial, no participants were reported to ...

Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight and keep it off. First head-to-head trial compares tirzepatide and semaglutide - Results are in ...